Cepharanthine aggravated atherosclerosis and liver injury in Apoe −/− and Ldlr −/− mice

Cardiology Plus · Published 2025-01-01 · DOI 10.1097/cp9.0000000000000109

Authors being retrieved — see the publisher record. https://doi.org/10.1097/cp9.0000000000000109

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

The role of myeloperoxidase as a biomarker in atherosclerotic cardiovascular disease · Cardiology Plus · 2024 · Same journal
The safety and efficacy of the microaxial SynFlow 3.0 flow pump system for patients undergoing high-risk percutaneous coronary intervention · Cardiology Plus · 2025 · Same journal
Single-cell sequencing and machine learning identify endoplasmic reticulum stress as a mechanism and therapeutic target in heart failure · Cardiology Plus · 2026 · Same journal
Cardio-oncology training: a look under the hood · Cardiology Plus · 2025 · Same journal
Histological validation of artificial intelligence–driven automatic plaque characterization in coronary OCT: a head-to-head comparison with clinicians · Cardiology Plus · 2025 · Same journal
New insights into atherosclerotic cardiovascular disease through the lens of metabolism: expanding our approach · Cardiology Plus · 2025 · Same journal
Rats subject to extracorporeal membrane oxygenation have improved cardiac function following anticoagulation and reversal with factor IXa aptamer-antidote oligonucleotide pair · Cardiology Plus · 2025 · Same journal
Cardiac light-chain amyloidosis: a clinical update · Cardiology Plus · 2026 · Same journal
Doxorubicin-induced cardiotoxicity: mechanisms, surveillance, and prevention strategies · Cardiology Plus · 2026 · Same journal
Mitochondrial transplantation for cardiovascular diseases: opportunities and challenges—a review · Cardiology Plus · 2026 · Same journal